Cargando…

Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery

BACKGROUND: Recurrent and metastatic thyroid cancer is more invasive and can transform to dedifferentiated thyroid cancer, thus leading to a severe decline in the 10-year survival. The thyroid-stimulating hormone receptor (TSHR) plays an important role in differentiation process. We aim to find a th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xue, Wu, Yonglin, Xu, Shaojie, Li, Hanning, Peng, Chengcheng, Cui, Xiaoqing, Dhoomun, Deenraj Kush, Wang, Ge, Xu, Tao, Dong, Menglu, Li, Xingrui, Du, Yaying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197823/
https://www.ncbi.nlm.nih.gov/pubmed/37208644
http://dx.doi.org/10.1186/s12902-023-01360-z
_version_ 1785044623914172416
author Yang, Xue
Wu, Yonglin
Xu, Shaojie
Li, Hanning
Peng, Chengcheng
Cui, Xiaoqing
Dhoomun, Deenraj Kush
Wang, Ge
Xu, Tao
Dong, Menglu
Li, Xingrui
Du, Yaying
author_facet Yang, Xue
Wu, Yonglin
Xu, Shaojie
Li, Hanning
Peng, Chengcheng
Cui, Xiaoqing
Dhoomun, Deenraj Kush
Wang, Ge
Xu, Tao
Dong, Menglu
Li, Xingrui
Du, Yaying
author_sort Yang, Xue
collection PubMed
description BACKGROUND: Recurrent and metastatic thyroid cancer is more invasive and can transform to dedifferentiated thyroid cancer, thus leading to a severe decline in the 10-year survival. The thyroid-stimulating hormone receptor (TSHR) plays an important role in differentiation process. We aim to find a therapeutic target in redifferentiation strategies for thyroid cancer. METHODS: Our study integrated the differentially expressed genes acquired from the Gene Expression Omnibus database by comparing TSHR expression levels in the Cancer Genome Atlas database. We conducted functional enrichment analysis and verified the expression of these genes by RT-PCR in 68 pairs of thyroid tumor and paratumor tissues. Artificial intelligence-enabled virtual screening was combined with the VirtualFlow platform for deep docking. RESULTS: We identified five genes (KCNJ16, SLC26A4, TG, TPO, and SYT1) as potential cancer treatment targets. TSHR and KCNJ16 were downregulated in the thyroid tumor tissues, compared with paired normal tissues. In addition, KCNJ16 was lower in the vascular/capsular invasion group. Enrichment analyses revealed that KCNJ16 may play a significant role in cell growth and differentiation. The inward rectifier potassium channel 5.1 (Kir5.1, encoded by KCNJ16) emerged as an interesting target in thyroid cancer. Artificial intelligence-facilitated molecular docking identified Z2087256678_2, Z2211139111_1, Z2211139111_2, and PV-000592319198_1 (-7.3 kcal/mol) as the most potent commercially available molecular targeting Kir5.1. CONCLUSION: This study may provide greater insights into the differentiation features associated with TSHR expression in thyroid cancer, and Kir5.1 may be a potential therapeutic target in the redifferentiation strategies for recurrent and metastatic thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-023-01360-z.
format Online
Article
Text
id pubmed-10197823
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101978232023-05-20 Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery Yang, Xue Wu, Yonglin Xu, Shaojie Li, Hanning Peng, Chengcheng Cui, Xiaoqing Dhoomun, Deenraj Kush Wang, Ge Xu, Tao Dong, Menglu Li, Xingrui Du, Yaying BMC Endocr Disord Research BACKGROUND: Recurrent and metastatic thyroid cancer is more invasive and can transform to dedifferentiated thyroid cancer, thus leading to a severe decline in the 10-year survival. The thyroid-stimulating hormone receptor (TSHR) plays an important role in differentiation process. We aim to find a therapeutic target in redifferentiation strategies for thyroid cancer. METHODS: Our study integrated the differentially expressed genes acquired from the Gene Expression Omnibus database by comparing TSHR expression levels in the Cancer Genome Atlas database. We conducted functional enrichment analysis and verified the expression of these genes by RT-PCR in 68 pairs of thyroid tumor and paratumor tissues. Artificial intelligence-enabled virtual screening was combined with the VirtualFlow platform for deep docking. RESULTS: We identified five genes (KCNJ16, SLC26A4, TG, TPO, and SYT1) as potential cancer treatment targets. TSHR and KCNJ16 were downregulated in the thyroid tumor tissues, compared with paired normal tissues. In addition, KCNJ16 was lower in the vascular/capsular invasion group. Enrichment analyses revealed that KCNJ16 may play a significant role in cell growth and differentiation. The inward rectifier potassium channel 5.1 (Kir5.1, encoded by KCNJ16) emerged as an interesting target in thyroid cancer. Artificial intelligence-facilitated molecular docking identified Z2087256678_2, Z2211139111_1, Z2211139111_2, and PV-000592319198_1 (-7.3 kcal/mol) as the most potent commercially available molecular targeting Kir5.1. CONCLUSION: This study may provide greater insights into the differentiation features associated with TSHR expression in thyroid cancer, and Kir5.1 may be a potential therapeutic target in the redifferentiation strategies for recurrent and metastatic thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-023-01360-z. BioMed Central 2023-05-19 /pmc/articles/PMC10197823/ /pubmed/37208644 http://dx.doi.org/10.1186/s12902-023-01360-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Xue
Wu, Yonglin
Xu, Shaojie
Li, Hanning
Peng, Chengcheng
Cui, Xiaoqing
Dhoomun, Deenraj Kush
Wang, Ge
Xu, Tao
Dong, Menglu
Li, Xingrui
Du, Yaying
Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery
title Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery
title_full Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery
title_fullStr Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery
title_full_unstemmed Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery
title_short Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery
title_sort targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197823/
https://www.ncbi.nlm.nih.gov/pubmed/37208644
http://dx.doi.org/10.1186/s12902-023-01360-z
work_keys_str_mv AT yangxue targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT wuyonglin targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT xushaojie targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT lihanning targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT pengchengcheng targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT cuixiaoqing targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT dhoomundeenrajkush targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT wangge targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT xutao targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT dongmenglu targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT lixingrui targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery
AT duyaying targetingtheinwardrectifierpotassiumchannel51inthyroidcancerartificialintelligencefacilitatedmoleculardockingfordrugdiscovery